Table 1.

Efficacy comparison of PF00299804 and other EGFR TKIs

IC50, μmol/L
Cell lineGenetic statusPF00299804GefitinibLapatinibBIBW-2992CI-1033
SNU-216HER2 amp0.007 ± 0.00040.39 ± 0.020.02 ± 0.0030.02 ± 0.0010.15 ± 0.008
N87HER2 amp0.002 ± 0.00040.23 ± 0.020.01 ± 0.0010.02 ± 0.0010.13 ± 0.002
SNU-1KRAS mt3.8 ± 1.23.8 ± 0.921.95 ± 0.0542.96 ± 0.61.61 ± 0.03
SNU-5MET amp2.8 ± 0.72>10>102.32 ± 0.023.93 ± 0.74
SNU-16FGFR2 amp3.73 ± 1.55.56 ± 0.941.52 ± 0.0691.69 ± 0.111.84 ± 0.09
SNU-4841.52 ± 0.48>100.99 ± 0.0141.57 ± 0.040.99 ± 0.66
SNU-601KRAS mt3.79 ± 0.8>103.70 ± 0.1486.14 ± 0.81.22 ± 0.64
SNU-6201.04 ± 0.01>101.39 ± 0.2401.04 ± 0.022.13 ± 0.03
SNU-638MET amp1.99 ± 0.003>104.94 ± 0.3266.03 ± 2.334.51 ± 0.48
SNU-668KRAS mt4.96 ± 0.19>10>102.24 ± 0.582.32 ± 0.01
SNU-7191.58 ± 0.01>10>103.87 ± 0.424.95 ± 0.64

NOTE: Shown are the IC50 values of each drug using MTT assay, as described in Materials and Methods on gastric cancer cell lines.